PRKDC and ovarian cancer: Fok et al. demonstrated that the highly selective DNA-PKcs inhibitor AZD7648 is an efficient sensitizer of radiation- and doxorubicin-induced DNA damage [20] and enhanced the therapeutic efficacy for patients with ovarian cancer [21].